Abstract
Expectant therapy for early Group B Streptococcus onset septicemia must provide coverage against other microrganisms, such as L. Monocytogenes, H. Influenzae and S. Pneumoniae. It is possible to administer a combination of antimicrobial agents with activity against all or the most likely pathogens. Thus initial expectant therapy includes a broad spectrum semisynthetic penicillin (e.g. ampicillin) and an aminoglycoside (e.g. netilmicin). Vancomycin, teicoplanin and cefotaxime may also be used. Supportive therapy consists of temperature control, i.v. administration of fluids, acid-base balance and electrolytes monitoring, seizures control and ventilation. I.V. immunoglobulins, granulocyte and serum transfusion are also used. The G-Golony Stimulating Factor (G-CSF, filgastrim) usage is also reported.
| Original language | Italian |
|---|---|
| Pages (from-to) | 305-306 |
| Number of pages | 2 |
| Journal | Pediatria Medica e Chirurgica |
| Volume | 17 |
| Issue number | 4 |
| Publication status | Published - 1995 |
Fingerprint
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
LA TERAPIA DELL'INFEZIONE NEONATALE DA STREPTOCOCCO BETA-EMOLITICO DI GRUPPO B. / Aabas, A.; Berzioli, M.; Brisotto, P.; Caliandro, P.; Chirico, G.; Colonna, F.; Curro, V.; De Mitri, B.; De Vonderweid, U.; Del Prete, A.; Giorgi, R.; Latini, G.; Morandi, F.; Passerini, C.; Quartulli, L.; Rosati, E.; Taborelli, A.; Visona, E.; Zanini, R.
In: Pediatria Medica e Chirurgica, Vol. 17, No. 4, 1995, p. 305-306.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - LA TERAPIA DELL'INFEZIONE NEONATALE DA STREPTOCOCCO BETA-EMOLITICO DI GRUPPO B
AU - Aabas, A.
AU - Berzioli, M.
AU - Brisotto, P.
AU - Caliandro, P.
AU - Chirico, G.
AU - Colonna, F.
AU - Curro, V.
AU - De Mitri, B.
AU - De Vonderweid, U.
AU - Del Prete, A.
AU - Giorgi, R.
AU - Latini, G.
AU - Morandi, F.
AU - Passerini, C.
AU - Quartulli, L.
AU - Rosati, E.
AU - Taborelli, A.
AU - Visona, E.
AU - Zanini, R.
PY - 1995
Y1 - 1995
N2 - Expectant therapy for early Group B Streptococcus onset septicemia must provide coverage against other microrganisms, such as L. Monocytogenes, H. Influenzae and S. Pneumoniae. It is possible to administer a combination of antimicrobial agents with activity against all or the most likely pathogens. Thus initial expectant therapy includes a broad spectrum semisynthetic penicillin (e.g. ampicillin) and an aminoglycoside (e.g. netilmicin). Vancomycin, teicoplanin and cefotaxime may also be used. Supportive therapy consists of temperature control, i.v. administration of fluids, acid-base balance and electrolytes monitoring, seizures control and ventilation. I.V. immunoglobulins, granulocyte and serum transfusion are also used. The G-Golony Stimulating Factor (G-CSF, filgastrim) usage is also reported.
AB - Expectant therapy for early Group B Streptococcus onset septicemia must provide coverage against other microrganisms, such as L. Monocytogenes, H. Influenzae and S. Pneumoniae. It is possible to administer a combination of antimicrobial agents with activity against all or the most likely pathogens. Thus initial expectant therapy includes a broad spectrum semisynthetic penicillin (e.g. ampicillin) and an aminoglycoside (e.g. netilmicin). Vancomycin, teicoplanin and cefotaxime may also be used. Supportive therapy consists of temperature control, i.v. administration of fluids, acid-base balance and electrolytes monitoring, seizures control and ventilation. I.V. immunoglobulins, granulocyte and serum transfusion are also used. The G-Golony Stimulating Factor (G-CSF, filgastrim) usage is also reported.
UR - http://www.scopus.com/inward/record.url?scp=0028818764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028818764&partnerID=8YFLogxK
M3 - Articolo
C2 - 7491323
AN - SCOPUS:0028818764
VL - 17
SP - 305
EP - 306
JO - Pediatria Medica e Chirurgica
JF - Pediatria Medica e Chirurgica
SN - 0391-5387
IS - 4
ER -